Clinical Trials Browser

Phase 2/3 × Interventional × Uveal Melanoma × Clear all

NCT06581406 2026-04-02

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Phase 2/3 Recruiting

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT05987332 2026-02-17

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Phase 2/3 Active not recruiting

Uveal Melanoma, Melanoma

NCT00811200 2009-07-02

TORR

Phase 2/3 Unknown

Uveal Melanoma, Macular Degeneration, Melanoma, Retinal Diseases, Choroid Diseases